Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
|Podcasts|January 14, 2022
Pharmacy Focus: Psychedelic Pharmacy - Episode 3
Colonel Dallas Hack discussed the development of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder
Advertisement
In this episode, Colonel Dallas Hack discussed the development of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder, as well as how his own background led him to this research. In the interview, Hack said he believes a derivative could improve access as well as acceptance of the psychedelic drug.
Advertisement
Related to this article
Marie-Claire Seeley, RN, MNurs, PhD, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
In a Pharmacy Times interview, study coauthor William J. Peppard, PharmD, discusses the association between suzetrigine and fewer opioid refills after knee replacement, the limits of the evidence, and the access barriers pharmacists can help patients navigate.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
3
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
4
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
5